Technology Overview

Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.

Both treatment approaches harness the patient’s own immune system to fight the cancer.

Read more about Virus-based Immunotherapy (ONCOS-102)

Read more about Peptide-based Immunotherapy (TG01)

Targovax brings together two unique & complementary immuno-oncology technologies